Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of lenalidomide in induction and post-induction treatment for de novo acute myeloid leukemia with chromosome 5 abnormalities
2009-011090-33Phase 2Terminated
- Sponsor
- Fundación PETHEMA
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in acute myeloid leukemia (AML), sponsored by Fundación PETHEMA. Primary endpoint: Duration of remission. Started May 2009; status: terminated.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-011090-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011090-33.